Fiche personne


Territoire

Alsace

Statut

Hospitalier

Équipes/plateformes

Hématologie

Recherche

Expertises :
- Clinique:Oncologie Médicale
- Clinique:Hématologie
- Cancer:Leucémies
- Cancer:Lymphomes

Publications


Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study.

Meunier M, Thepot S, Nimubona S, Veloso M, Lefebvre T, Karim Z, Ropert-Bouchet M, Garban F, Amé S, Reynes C, Salanoubat C, Parinet V, Laribi K, Eftekhari P, Delaunay J, Venton G, Santana C, Cheze S, Dimicoli-Salazar S, Toma A, Molimard M, Fenaux P, Rolland-Neyret V, David-Tchouda S, Park S

Haematologica. 2026 09 24;:

[Sexual and reproductive life of men and women with chronic myeloid leukemia: Opinion and practical considerations of the Fi-LMC group].

Huguet F, Ame S, Balsat M, Becquart C, Berger M, Cony-Makhoul P, Damase-Michel C, Dubruille V, Escoffre-Barbe M, Legros L, Penot A, Roth-Guepin G, Simonet-Boissard M, Nicolini F

Bull Cancer. 2026 08 5;:

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.

Nicolini FE, Etienne G, Huguet F, Charbonnier A, Roth-Guépin G, Escoffre-Barbe M, Dubruille V, Johnson-Ansah H, Rousselot P, Legros L, Parry A, Roy L, Coiteux V, Lenain P, Ianotto JC, Doublet C, Orvain C, Simonet-Boissard M, Chrétien ML, Penot A, Meunier M, Amé S, Hermet E, Quittet P, Lapusan S, Schwiertz V, Cayuela JM, Mauté C, Réa D, Morisset S, Mahon FX, Dulucq S

Lancet Haematol. 2026 05;13(5):e315-e326

Voir plus